<![CDATA[Transformational Utah Investment in Artificial Intelligence and Computing to Advance Health and Discovery]]>

Press Release|Articles|May 6, 2026 Transformational Utah Investment in Artificial Intelligence and Computing to Advance Health and Discovery Author(s)Huntsman Cancer Institute Listen0:00 / 0:00 Key Takeaways A new AI supercomputer, accessible to all Utah state universities, will be operated through the Center for High Performance Computing to scale research and entrepreneurship workflows. UHAIV will re-architect the Utah Population Database to enable modern AI analytics while maintaining stringent privacy, data security, and governance expectations for sensitive longitudinal records. Co-leadership by Huntsman Cancer Institute and University of Utah Health aims to translate AI capabilities into faster advances across oncology and other diseases, spanning risk stratification to survivorship. Complementary philanthropy, including a $10 million Huntsman Family Foundation gift, is intended to catalyze public-private partnerships, biopharma innovation, and high-skill workforce growth statewide.SHOW MORE The State of Utah has made a visionary investment in AI and advanced computing infrastructure to advance research. The University of Utah, joined with internal entities, including Huntsman Cancer Institute, today expressed deep gratitude to the State of Utah for its visionary investment in major new health and technology initiatives, including support for the Utah Health Artificial Intelligence Vault (UHAIV) and advanced computing infrastructure. The investment will enable a new AI supercomputer that will be accessible to all state universities in Utah.Together, these new investments, totaling more than $33 million, represent a defining moment for health and discovery—positioning the state to lead the nation in AI-enabled health innovation, while ensuring that impactful resources are stewarded responsibly and for the benefit of Utahns.“This is a powerful example of what becomes possible when a state chooses to invest boldly in the health and future of its people,” said Taylor Randall, president of the University of Utah. “Utah’s leadership understands that world-class discovery, advanced computing, and responsible data stewardship are essential to improving the lives of patients, families, and communities across our state. We are deeply grateful for this partnership and the trust it represents, and we are committed to delivering innovation that serves the public good.”Stewarding a One-of-a-Kind Public ResourceCentral to this work is UHAIV—a plan to develop a secure, modern platform designed to unlock the next era of discovery from one of Utah’s most extraordinary public assets, the Utah Population Database (UPDB). For decades, the UPDB has supported landmark discoveries in cancer, cardiovascular disease, Alzheimer’s disease, and other conditions.UHAIV will modernize the UPDB to enable and develop advanced AI analytics within a secure environment, while maintaining the highest standards of privacy, data security, and ethical oversight.Huntsman Cancer Institute will play a key stewardship role in advancing this initiative, ensuring that the power of AI is applied thoughtfully and responsibly to accelerate discovery. For more than two decades, Huntsman Cancer Institute has managed the UPDB. The UPDB has powered landmark advances in cancer genetics, including the identification of inherited risk genes for breast and ovarian cancer (BRCA1 and BRCA2), melanoma (CDKN2A/p16), and colon cancer (APC)—discoveries that have reshaped cancer risk assessment, screening guidelines, and prevention worldwide, cementing Utah’s place as an internationally recognized contributor to pivotal health discoveries in cancer and other diseases.However, current UPDB data architecture is not compatible with innovations in data science and AI. The UHAIV project will be a university-wide initiative, jointly managed by Bradley Cairns, PhD, CEO of Huntsman Cancer Institute, and James Hotaling, MD, chief innovation officer at Universityof Utah Health. By pairing UHAIV with AI computational infrastructure, including Utah's new AI supercomputer, researchers will gain unprecedented capabilities to accelerate breakthroughs in prevention, early detection, personalized treatments, and survivorship across numerous diseases—while ensuring sensitive and private data remains protected.The State of Utah’s complementary investment in advanced computing infrastructure significantly expands the university’s research capacity and establishes a foundation for a statewide AI ecosystem—one that supports researchers, clinicians, educators, and innovators across Utah. This supercomputer will be overseen by the university’s Center for High Performance Computing at the Scientific Computing Institute, led by Manish Parashar, PhD, chief AI officer at the University of Utah.“Infrastructure is the engine behind AI-enabled innovation,” Parashar said. “We’re grateful the state recognizes these investments as essential to keeping Utah at the forefront of AI. Once these resources are online, researchers and entrepreneurs will be able to move from concept to application at scale much faster.”These capabilities will accelerate discovery, strengthen Utah’s competitiveness in the life sciences, and support collaboration across institutions, disciplines, and communities—ensuring that the benefits of innovation extend beyond a single campus.Beyond scientific discovery, UHAIV and the AI supercomputer are expected to catalyze economic growth by enabling new public-private partnerships, supporting biotechnology and pharmaceutical innovation, and creating high-skill, high-wage jobs across Utah’s life sciences and technology sectors.“These investments are not just about technology,” said Bob Carter, MD, PhD, CEO of University of Utah Health. “They are about people—patients seeking better outcomes, families hoping for answers, and communities building a stronger future. Utah’s commitment makes that progress possible.”“We are grateful for the state’s leadership and partnership,” said Peter Huntsman, chairman andCEO of Huntsman Cancer Foundation. “Together, we are building a future where discovery moves faster, care reaches farther, and innovation serves everyone.”Peter and Brynn Huntsman and the Huntsman Family Foundation generously contributed $10 million to the University of Utah to catalyze the supercomputer project. Peter Huntsman worked closely with legislative leaders during the session to advocate for this initiative. NewsletterStay up to date on the most recent and practice-changing oncology dataSubscribe Now! Related ContentMentorship Is Key to Advance the Next Generation of Oncology ResearchersByKyle Doherty May 7th 2026Women With Bladder Cancer Face Diagnostic Delays as Symptoms Mimic UTIs, Experts WarnByKyle Doherty May 7th 2026Daraxonrasib Monotherapy Elicits Meaningful Responses in Previously Treated, RAS-Mutated Pancreatic CancerByCourtney FlahertyMay 7th 2026Sylvester Comprehensive Cancer Center Identifies a Screening Gap to Prevent a Type of Leukemia in the U.S.BySylvester Comprehensive Cancer CenterMay 7th 2026FDA Completes Type A Meeting Following CRL for Tabelecleucel in EBV+ R/R Post-Transplant Lymphoproliferative DiseaseByChris RyanMay 7th 2026 Latest CMEVideoProactive Adverse Event Management for HER2+ BTC TreatmentsRahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCOView moreMultimediaCommunity Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for MelanomaYana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR View moreVirtual EventWisconsin Association of Hematology and Oncology1 Session is Available!View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Empire State Hematology & Oncology SocietySeth A. Wander, MD, PhD; Girish Kunapareddy, MDView moreVirtual EventArkansas Association of Cancer Professionals2 Sessions are Available!View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | South Carolina Oncology SocietySeth A. Wander, MD, PhD; Kit Lu, MDView moreVideo19th Annual New York GU Cancers Congress®Maha Hussain, MD, FACP, FASCO; Daniel P. Petrylak, MDView moreIn-Person + Virtual EventGo to PER in ChicagoMay 29-31, 2026View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Tennessee Oncology Practice SocietySeth A. Wander, MD, PhD; Kamel Abou Hussein, MDView moreVirtual EventKansas Society of Clinical Oncology1 Session is Available!View moreVideoA Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCRView moreVideoEvolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular TestingEileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPHView moreVideoCases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple MyelomaC. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MDView moreVideoTumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLCBalazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MDView moreVideoMedical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic ApproachesRami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MDView moreVideoPER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging StrategiesJonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhDView moreVideoMedical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted TherapiesVinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MSView moreVideoMedical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple MyelomaC. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MDView moreVideoMedical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 DysregulationRebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhDView moreVideoCases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical InsightsGail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHSView moreVideoMedical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast CancerWilliam J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhDView moreVideoGI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal CancerJohn H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MDView moreVideoBreast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer TreatmentJoyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCOView moreMultimediaEstablishing the Rationale for ADC and ICI Combinations in TNBCVirginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCOView moreMultimediaBreaking Down the Rationale for Targeting TROP2 in TNBCFilipa Lynce, MD; Rita Nanda, MDView moreMultimediaDissecting Clinical Trial and Real-World Data for ADCs in TNBCFilipa Lynce, MD; Rita Nanda, MDView moreMultimediaEvaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MDView moreAudioBreaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLCRahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MSView moreVideoOptimizing Treatment for Biliary Tract CancersGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreVideoCross-Disease Integration of Immunotherapy InnovationsGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreAudioPractical Considerations and Future Directions for New Treatment Strategies in SCLCRahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhDView moreMultimediaExpert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DScView moreVideoBroadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular CarcinomaGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreMultimediaPER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – NursingAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCOView moreMultimediaExpert Roundtable and Panel Discussions: Current and Future Landscape of TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCOView moreVideoShow Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast CancerAna C. Garrido-Castro, MD; Pedram Razavi, MD, PhDView moreAudioNavigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New OptionsRahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhDView moreVideoMedical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk AssessmentJason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MDView moreMultimediaReady for Radioligand Therapy? Patient Selection and Sequencing SimplifiedJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaWorking Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary CareJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaBURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate CancerJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaImaging Matters: Decoding PSMA PET for Better Decision-MakingJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaRadioligand Therapy 101: The Science Behind the StrategyJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreVideo Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease ContinuumTina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhDView moreMultimediaCommunity Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary TeamYana G. Najjar, MD; Sapna Patel, MDView moreVideoA New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCsSandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHSView moreVideoNavigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVOSriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRSView moreVideoEnhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment StrategiesAna Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACPView moreVideo(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient OutcomesMichelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPOView more Trending on OncLive1Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 20262Daraxonrasib Monotherapy Elicits Meaningful Responses in Previously Treated, RAS-Mutated Pancreatic Cancer3ASCO 2026 TNBC Deep Dive: Breast Cancer Experts Preview Practice-Informing Studies4FDA Completes Type A Meeting Following CRL for Tabelecleucel in EBV+ R/R Post-Transplant Lymphoproliferative Disease5Women With Bladder Cancer Face Diagnostic Delays as Symptoms Mimic UTIs, Experts Warn